| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
1996-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2000-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62ee83767d65074c3e298fac3342af40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af3f0ba449ce2cee0077c59bf0d6dd14 |
| publicationDate |
2000-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AP-862-A |
| titleOfInvention |
Oxygenated heterocycle containing sulfonamide inhibitors of aspartyl protease. |
| abstract |
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting fflV-1 and HIV-2 protease activity and consequently, may be advantageously used as anu-v.ral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention. |
| priorityDate |
1995-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |